How Bristol-Myers' big buy could spur ripples for pharma M&A | BioPharma Dive

How Bristol-Myers' big buy could spur ripples for pharma M&A | BioPharma Dive

More reads

• Bristol’s codeword for Celgene during takeout negotiations was “champagne.” (Bloomberg)
• How much does it cost to hire a top pharma exec to run a biotech? (Endpoints News)
• How Bristol-Myers' big buy could spur ripples for pharma M&A (Biopharma Dive)
• The $9 Billion Upcharge: How Insurers Kept Extra Cash From Medicare (WSJ)